JAMA Otolaryngology–Head & Neck Surgery

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

Retrieved on: 
Thursday, November 2, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Knowledge, Dell Medical School, University of Washington School of Medicine, SMMT, University of Colorado School of Medicine, Associate, Therapy, University, Lung cancer, Head, MD, University of Texas at Austin, Drug, University of Ottawa Heart Institute, Thyroid, Summit, Drug development, Senior, Quality of life, Lung, Disease, JAMA Otolaryngology–Head & Neck Surgery, Immunotherapy, Patient, Moses Austin, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.
  • We are very excited to welcome Laura to our team.”
    Dr. Chow remains in active clinical practice as a medical oncologist specialized in lung and head and neck cancers.
  • She joins Summit from Fate Therapeutics, where she was the Vice President of Clinical Development in Solid Tumors.
  • Chow’s experience being on the ground floor of cancer immunotherapy is unmatched,” added Dr. Allen S. Yang, Chief Medical Officer at Summit.

Los Angeles Center for Ear, Nose, Throat and Allergy Opens Pasadena Office

Retrieved on: 
Wednesday, November 1, 2023
Ear, Suite, JAMA Otolaryngology–Head & Neck Surgery, Medicine, La Paloma Addition, Texas

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) announced today the opening of their new location in Pasadena, CA. LA CENTA currently has eight locations throughout LA, making Pasadena their ninth.

Key Points: 
  • LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) announced today the opening of their new location in Pasadena, CA.
  • Founded on the principles of accessibility and availability, LA CENTA is working to improve the quality of community healthcare in Los Angeles and beyond, especially in underserved communities.
  • As with their other offices, LA CENTA will offer a variety of high-quality, university caliber medical services at their Pasadena location.
  • Categories include: Ear & Audiology, Sinus/Nasal & Allergy, Throat & Voice, Head & Neck, and Throat Disorders.

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Education, PDSB, Head, Survival, Infection, HPV16, Head and Neck Cancer Alliance, Cancer, Hope, Rehabilitation, Research, JAMA Otolaryngology–Head & Neck Surgery, ASCO, Organization, Estate (law), Journal, Patient, Swallow, Annual general meeting, HNSCC, HPV, Oral, MPA, Trial of the century, FDA, Pembrolizumab, Death, Society, Food, Safety, Disease, Pharmaceutical industry

FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced its support for Oral, Head & Neck Cancer Awareness Month in April and Oral, Head & Neck Cancer Awareness Week, April 16-22, both of which are organized by the Head & Neck Cancer Alliance (HCNA).

Key Points: 
  • FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced its support for Oral, Head & Neck Cancer Awareness Month in April and Oral, Head & Neck Cancer Awareness Week, April 16-22, both of which are organized by the Head & Neck Cancer Alliance (HCNA).
  • PDS Biotech recognizes the important role and dedication of patient organizations, such as the HCNA and the U.K.-based Swallows Head & Neck Cancer Support Group (The Swallows) in not only raising awareness of oral, head and neck cancer, but also in providing advice, information and education to those impacted by the disease.
  • PDS Biotech recently announced it is planning to initiate a randomized, controlled Phase 3 trial of the company’s lead clinical candidate, PDS0101, in combination with KEYTRUDA® (pembrolizumab) for the potential treatment of human papillomavirus (HPV)16-positive head and neck cancer.
  • We are proud to join these organizations during the month of April to celebrate the progress made while acknowledging that more is needed.

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Retrieved on: 
Monday, March 6, 2023
Ovarian cancer, CD70, Mesothelin, MPM, ADAP, TCR, Specialization, IND, Webcast, Engineering, Platinum, Ovary, Neoplasm, Growth, Mesothelioma, Synovial sarcoma, TNBC, Therapy, Nivolumab, JAMA Otolaryngology–Head & Neck Surgery, PRAME, Patient, TD, Truc, Simple squamous epithelium, Carcinoma, Survival, Cancer, EST, SPEAR, BLA, Otorhinolaryngology, Overalls, PDUFA, Bank, Holding company, Pharmaceutical industry, Vaccine, Fine chemical, Birth control, Cryptocurrency, EU

Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to create a preeminent cell therapy company for solid tumors.

Key Points: 
  • Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to create a preeminent cell therapy company for solid tumors.
  • The combined company will drive forward its pipeline of cell therapies aimed at treating multiple cancers with high unmet medical needs.
  • Focus and specialization are critical in the cell therapy space and we believe the combined company has the technologies necessary to succeed.
  • The combined company has a team of leading cell therapy experts led by Adrian Rawcliffe, the CEO of Adaptimmune.

Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Retrieved on: 
Monday, January 30, 2023
Cell, PLOS One, Weight gain, ST, Triiodothyronine, MD, Thyroid, Constipation, North Central Cancer Treatment Group, Synthetic control method, PMID, Amnesia, TSX, Thyroid hormones, JAMA Otolaryngology–Head & Neck Surgery, Survival, FACS, PSH, Bachelor of Science, Depression, FRCSC, University, Institute for Quality and Efficiency in Health Care, Patient, The Control Group, Hypothyroidism, FSE, Faculty, Thyroidectomy, Medical school, Quality, Haemophilia, Control Group, Metabolism, Dentistry, Pharmaceutical industry, Medicine, T4

The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.

Key Points: 
  • The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.
  • The thyroid gland of each Treatment Group subject was removed, prepared with minimal manipulation, and transplanted into the pre-implanted Cell Pouch.
  • Following thyroidectomy in the Treatment Group, the T3 and T4 levels fell initially but subsequently recovered to normal or near-normal levels following thyroid transplant into the Cell Pouch.
  • Control Group subjects received the Cell Pouch implant and underwent total thyroidectomy but did not receive a thyroid transplant.

Global Radiology Positioning Aids Market Report 2022 to 2027: Featuring AADCO Medical, Abecca Healthcare, Bionix and CIVCO Radiotherapy Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Medical Devices, Health, Hospitals, Health Technology, Radiology, Biotechnology, Pediatrics, JAMA Otolaryngology–Head & Neck Surgery, Ansoff Matrix, Emotion, Competitive analysis, Porter's five forces analysis, Risk, Wilford Hall Ambulatory Surgical Center, COVID-19, Growth, Market development, Observation, SWOT, Investment, Geography, Table, USD, Impact, Thorax, Medical device, Marketing, Retail, Risk management, Medical imaging, Hospital

The Global Radiology Positioning Aids Market is estimated to be USD 302.12 Mn in 2022 and is expected to reach USD 425.72 Mn by 2027, growing at a CAGR of 7.1%.

Key Points: 
  • The Global Radiology Positioning Aids Market is estimated to be USD 302.12 Mn in 2022 and is expected to reach USD 425.72 Mn by 2027, growing at a CAGR of 7.1%.
  • The report presents a detailed Ansoff matrix analysis for the Global Radiology Positioning Aids Market.
  • The analyst analyses the Global Radiology Positioning Aids Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Radiology Positioning Aids Market.

EQS-News: Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy

Retrieved on: 
Thursday, February 2, 2023
Constipation, Institute for Quality and Efficiency in Health Care, Thyroid, ST, University, Thyroidectomy, Amnesia, Quality, Medical school, Bachelor of Science, Haemophilia, FSE, Depression, TSX, MD, FRCSC, PMID, Control Group, Weight gain, Survival, PLOS One, Metabolism, Patient, Hypothyroidism, JAMA Otolaryngology–Head & Neck Surgery, North Central Cancer Treatment Group, FACS, Triiodothyronine, Faculty, The Control Group, Thyroid hormones, Synthetic control method, PSH, Cell, Dentistry, Pharmaceutical industry, Medicine, T4

The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.

Key Points: 
  • The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.
  • The thyroid gland of each Treatment Group subject was removed, prepared with minimal manipulation, and transplanted into the pre-implanted Cell Pouch.
  • Following thyroidectomy in the Treatment Group, the T3 and T4 levels fell initially but subsequently recovered to normal or near-normal levels following thyroid transplant into the Cell Pouch.
  • Control Group subjects received the Cell Pouch implant and underwent total thyroidectomy but did not receive a thyroid transplant.

Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Infectious Diseases, Genetics, Pharmaceutical, Biotechnology, University, Hargreaves, Growth, SEC, Private Securities Litigation Reform Act, Drug discovery, Collectable, Lung, Ovarian cancer, Degenerative disease, Solution, Cancer, Annual report, Risk, Industry, Cooley LLP, Precision medicine, Forward-looking statement, Oncology, COVID-19, Genomics, Cloud computing, Genetic testing, Neoplasm, Form 10-K, Hand, Acquisition, NASDAQ, Webcast, Investor relations, Compliance, Legislation, Candidate, NSCLC, Reproductive health, Public health, JAMA Otolaryngology–Head & Neck Surgery, P.C, Laboratory, Overalls, Tissue, Therapy, Sale, Safety, Paclitaxel, Technology, Health, CEO, Review, Genetics, Biodistribution, H. Lee Moffitt Cancer Center & Research Institute, Investment, PK, Head, Research, Pharmaceutical industry, Vaccine, Risk management, Breast

Fulgent Pharma and Fulgent Genetics were previously both owned by Fulgent Therapeutics until 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics.

Key Points: 
  • Fulgent Pharma and Fulgent Genetics were previously both owned by Fulgent Therapeutics until 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics.
  • Fulgent Genetics track record of integrating acquisitions, strategic partnerships, and disciplined execution has been a key element in the companys growth.
  • Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.
  • In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives.

US Head & Neck Cancers Market and Competitive Landscape 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Health, Oncology, Epidemiology, JAMA Otolaryngology–Head & Neck Surgery, Competitive landscape, Prevalence, Patient, Research, Cancer, Head and Neck Cancer Alliance, Head, Otorhinolaryngology, View, Risk management, Pharmaceutical industry, Dietary supplement

The "US Head & Neck Cancers Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Head & Neck Cancers Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report US Head & Neck Cancers Market and Competitive Landscape Highlights - 2022, provides comprehensive insights into Head & Neck Cancers pipeline products, Head & Neck Cancers epidemiology, Head & Neck Cancers market valuations and forecast, Head & Neck Cancers drugs sales and competitive landscape in the US.
  • Head & Neck Cancers pipeline: Find out the products in clinical trials for the treatment of Head & Neck Cancers by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Head & Neck Cancers epidemiology: Find out the number of patients diagnosed (prevalence) with Head & Neck Cancers in the US
    Head & Neck Cancers drugs: Identify key products marketed and prescribed for Head & Neck Cancers in the US, including trade name, molecule name, and company
    Head & Neck Cancers drugs sales: Find out the sales revenues of Head & Neck Cancers drugs in the US
    Head & Neck Cancers market valuations: Find out the market size for Head & Neck Cancers drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Head & Neck Cancers drugs market share: Find out the market shares for key Head & Neck Cancers drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Head & Neck Cancers products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005439/en/

New 12-month Results from the VATRAC Trial Confirm Durable Efficacy of Aerin Medical’s VivAer® in Patients with Nasal Valve Collapse

Retrieved on: 
Tuesday, September 6, 2022
Science, Other Science, Research, Medical Supplies, Health, Medical Devices, Clinical Trials, Other Health, Otorhinolaryngology, ENT, Fatigue, JAMA Otolaryngology–Head & Neck Surgery, Technology, Division, Safety, CEO, NAO, YouTube, Nose, Exercise, Solution, Randomized controlled trial, International Forum of Allergy & Rhinology, Physician, LinkedIn, NVC, Ear, Network congestion, Headache, Quality of life, Multimedia, Sleep, Somnolence, Patient, Instagram, FDA, Eastern Virginia Medical School, Nasal congestion, Twitter, Excessive daytime sleepiness, Snoring, Prevalence, Epworth Sleepiness Scale, Freezing, CE marking, Adoption, Pharmaceutical industry, Birth control, Allergy, Facebook

This study demonstrates that treatment with VivAer is a compelling non-invasive alternative for NAO patients and reinforces physician confidence in the consistent and lasting results of this treatment.

Key Points: 
  • This study demonstrates that treatment with VivAer is a compelling non-invasive alternative for NAO patients and reinforces physician confidence in the consistent and lasting results of this treatment.
  • After primary endpoint analysis and unblinding, 31 patients were eligible for crossover, and all elected to undergo active VivAer treatment.
  • The VATRAC study outcomes demonstrate ongoing effectiveness and safety of VivAer, with treated patients reporting durable improvement from baseline at 12 months post-procedure.
  • 1 Silvers et al., Temperature-controlled radiofrequency device treatment of the nasal valve for nasal airway obstruction: A randomized controlled trial.